PrimeC Shows Promising Biomarker Shifts in Alzheimer's Trial
A drug developed for ALS shows biological activity in Alzheimer's, suggesting shared mechanisms across neurodegenerative diseases.
1,333 articles
A drug developed for ALS shows biological activity in Alzheimer's, suggesting shared mechanisms across neurodegenerative diseases.
A new Oxford tool using 5.6 million patient records shows serious statin muscle side effects are rare, yet 60% of eligible patients skip the drug.
Disabling the MTCH2 protein in human cells supercharges fat burning and halts new fat cell growth — a potential obesity breakthrough.
New evidence shows a well-timed workout can counteract the artery-damaging effects of a high-fat meal — but timing is everything.
New research links H. pylori infection to higher colorectal cancer risk, while gut-brain therapies show real promise for IBS sufferers.
A study of 90,000+ people finds every extra hour of uninterrupted sitting raises cancer mortality risk by 10%, but brief activity can reverse it.
A fractional laser shifted epigenetic markers at 83.9% of aging-linked DNA sites, with visible improvements lasting six months.
Sana Biotechnology's hypoimmune cell therapy may eliminate the need for lifelong immunosuppression in type 1 diabetes transplants.
Protagenic's PT00114 slashed stress-related cortisol markers and anxiety behaviors in rats, outperforming a standard CRF1 antagonist.
AlzeCure's NeuroRestore platform secures a landmark $2.2B licensing deal with QuantumCell, targeting Alzheimer's, Parkinson's, and depression.
A 52-week study shows patients with mild Alzheimer's can reliably complete unsupervised brain scans and cognitive tests at home.
A new in vivo therapy aims to reprogram macrophages inside the body using mRNA and lipid nanoparticles, potentially replacing complex cell transplants.